Ailani R K, Shah S P, Koyande D, Kudalkar S S, Kodge K, Deshmukh Y A
Dept. of Respiratory Medicine, B.Y.L. Nair Hospital, Bombay.
J Assoc Physicians India. 1995 Jan;43(1):36, 41.
An open two weeks short term trial of Ipratropium Bromide (IB) inhalation (0.02 mg per dose) was carried out in 20 stable asthamatics to study its efficacy and safety. Early significant rise in PEFR (P < 0.001) and FEV1 (P < 0.05) was observed after 15 min of IB inhalation and reached significant peak (P < 0.01) after 1 hour which was persistent beyond three hours after IB inhalation. No side effects were observed. It was concluded that Ipratropium Bromide Imhalation is safe and has efficient bronchodilatory effect on short term basis in stable asthmatics.
对20名稳定期哮喘患者进行了为期两周的异丙托溴铵（IB）吸入开放短期试验（每剂0.02毫克），以研究其疗效和安全性。吸入IB 15分钟后观察到呼气峰流速（PEFR）（P < 0.001）和第一秒用力呼气容积（FEV1）（P < 0.05）早期显著升高，1小时后达到显著峰值（P < 0.01），且在吸入IB后三小时以上仍持续。未观察到副作用。得出结论：异丙托溴铵吸入在稳定期哮喘患者短期使用时是安全的，且具有有效的支气管扩张作用。
Zotero 插件